Artelo Biosciences, Inc. (ARTL) Dividend History

Company News

• Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

  Artelo Biosciences presented data showing that its FABP5 inhibitor, ART26.12, demonstrated analgesic effects similar to naproxen in a rat model of osteoarthritis pain, with the potential for development as a non-opioid, non-steroidal alternative for chronic OA pain.

  GlobeNewswire Inc.
• Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th

  Artelo Biosciences, a clinical-stage pharmaceutical company, announced that its CEO, Gregory D. Gorgas, will participate in a fireside chat at the Maxim Group 2024 Virtual Healthcare Summit on October 16, 2024.

  GlobeNewswire Inc.
• Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

  Artelo Biosciences, a clinical-stage pharmaceutical company, announced that its CEO will be participating in the upcoming H.C. Wainwright Global Investment Conference. The company's presentation will be available on-demand, and management will be holding one-on-one meetings with investors.

  GlobeNewswire Inc.
• Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society

  ART26.12 shows efficacy in breast cancer-induced bone pain and diabetic neuropathy ART26.12 shows efficacy in breast cancer-induced bone pain and diabetic neuropathy

  GlobeNewswire Inc.
• Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24

  ART12.11 demonstrates comparable pharmacokinetics compared to Epidiolex® ART12.11 demonstrates comparable pharmacokinetics compared to Epidiolex®

  GlobeNewswire Inc.